| Adult Oncology |
Vazquez-Telewoda, Kimberly |
BTG International |
TheraSphere Humanitarian Device |
A Humanitarian Device Exemption use Protocol of TheraSphere For Treatment of Unresectable Primary or Secondary Liver Cancer |
| Adult Oncology |
Drost, Charlene |
Celgene Corporation |
MDS/AML |
Connect MDS/AML Disease Registry |
| Adult Oncology |
Vazquez-Telewoda, Kimberly |
Juno Therapeutics |
017006 |
A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients with Aggressive B-cell NHL (017006) |
| Adult Oncology |
Vazquez-Telewoda, Kimberly |
Juno Therapeutics |
017007 |
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting |
| Adult Oncology |
Vazquez-Telewoda, Kimberly |
Precision Rad/Onc |
Lung Immunotherapy |
A Prospective Trial Of Immunotherapy And Stereotactic Body Radiotherapy (Sbrt) For The Treatment Of Metastatic Lung Cancer: Sbrt Sensitization Of The Programmed Death-1 (Pd-1) Effect |
| Adult Oncology |
Vazquez-Telewoda, Kimberly |
Seer, Inc. |
020102 (SEERPRO) |
SEERPRO: A Prospective Blood Sample Collection Study to Evaluate A Panel of Protein-based Biomarkers |
| Adult Oncology |
Vazquez-Telewoda, Kimberly |
SPUH |
Medactionplan Pro (Map Pro) |
Integration Of A Comprehensive Medication Management System Called Medactionplan Pro (Map Pro) To Improve Patient Safety And Adherence Of Medication Therapy In The Outpatient Cancer Center At Saint Peter’s University Hospital |
| Breast Surgery |
Vazquez-Telewoda, Kimberly |
Alliance |
A011401 |
Randomized trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer |
| Breast Surgery |
Vazquez-Telewoda, Kimberly |
Caris Life Sciences |
TCBIO-001-0710 |
The Caris Biorepository Research Protocol |
| Breast Surgery |
Vazquez-Telewoda, Kimberly |
ECOG |
EA1151 |
Tomosynthesis Mammographic Imaging Screening Trial (TMIST) |
| Breast Surgery |
Vazquez-Telewoda, Kimberly |
NRG |
BR003 |
Randomized trial of adjuvant therapy comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node positive or high risk node negative triple negative invasive breast cancer |
| Dept. of Anesthesiology |
Drost, Charlene |
SPUH |
Continuous Electronic Monitoring |
Prevention and Detection of Respiratory Depression Associated with Administration of Neuraxial Morphine for Cesarean: The Role of continuous Electronic Monitoring |
| Dept. of Medicine |
|
AbbVie |
M20-404 |
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ABBV-47D11 in Adults Hospitalized with COVID-19 |
| Dept. of Medicine |
Vazquez-Telewoda, Kimberly |
Chiesi Therapeutics |
CUSA-081-HEM-01 (READY 1) |
A Phase 3, Randomized, Double-Blind, Active And Placebo-Controlled Sudy On The Use Of Cusa-081for Dysfunctional Central Venous Access Devices (Cv Ads) |
| Dept. of Medicine |
|
SPUH |
Early Markers Autism |
Development of Early Markers of Autism Spectrum Disorder (ASD) |
| Dept. of Medicine |
Vazquez-Telewoda, Kimberly |
SPUH |
Biomarkers in COVID-19 |
Clinical, Biochemical, and Immune Biomarkers in COVID-19: A Natural History Study |
| Dept. of Medicine |
|
SPUH |
Naptime Sleep Protocol |
Naptime Sleep Protocol |
| Dept. of Surgery |
Zanko, Joanna |
SPUH |
Nanoparticle Targeted Chemo |
Molecularly Defined Dendritic Polypeptide Nanoparticle-based Targeted Delivery of Chemotherapy |
| Genetics & Genomic Medicine |
Silva, Daniela |
Genzyme |
10-090 Gaucher MAIN and Pregnancy Sub-Registry |
10-090 Gaucher MAIN and Pregnancy Sub-Registry |
| Genetics & Genomic Medicine |
Silva, Daniela |
Genzyme |
10-091 Fabry MAIN and Pregnancy Sub-Registry |
10-091 Fabry MAIN and Pregnancy Sub-Registry |
| Genetics & Genomic Medicine |
Silva, Daniela |
Genzyme |
10-092 MPSI MAIN and Pregnancy Sub-Registry |
10-092 MPSI MAIN and Pregnancy Sub-Registry |
| Genetics & Genomic Medicine |
Silva, Daniela |
Genzyme |
10-093 Pompe MAIN and Pregnancy Sub-Registry |
10-093 Pompe MAIN and Pregnancy Sub-Registry |
| Genetics & Genomic Medicine |
Silva, Daniela |
Passage Bio, Inc. |
PBGM01-001 |
A Phase 1/2 Open-Label, Multicenter, Dose Ranging and Confirmatory Study to Assess the Safety, Tolerability and Efficacy of Single Dose of PBGM01 Delivered into the Cisterna Magna of Pediatric Subjects Aged 1 to 24 Months with Type 1 (Infantile) and Type 2a (Late Infantile) GM1 Gangliosidosis |
| Genetics & Genomic Medicine |
Silva, Daniela |
SPUH |
SPUH - Regional Center for Newborn Screening & Gen |
Newborn Screening and Genetic ServicesDFHS17NWB01246.02008 |
| Maternal Fetal Medicine |
Beche, Imene |
Columbia University |
ALPS FSP (AAAR5624) |
Childhood Pulmonary Complication |
| Maternal Fetal Medicine |
Beche, Imene |
Columbia University |
ALPS Neuro (AAAR5971) |
Childhood Cognitive Function in a birth cohort after a randomized trial of antenatal corticosteroids: The ALPS Neurocognitive follow up study.NIH |
| Maternal Fetal Medicine |
Beche, Imene |
Columbia University |
AWARE (AAAS3077) |
Activity in Women at Risk for Early delivery (AWARE) An Ancillary Study |
| Maternal Fetal Medicine |
Otarola, Sol |
Columbia University |
ECCHO-NFGS (AAAR4976) |
Environmental Contributors to Child Health Originating from the National Fetal Growth Study (ECCHO-NFGS) |
| Maternal Fetal Medicine |
Perez, Clara |
Columbia University |
Exosome CMV/Zika (AAAR7108) |
Maternal Plasma Exosome Testing to Detect Fetal Brain Injury Following CMV or Zika Infection |
| Maternal Fetal Medicine |
Beche, Imene |
Columbia University |
PROSPECT |
A randomized trial of Pessary and Progesterone for Pretern Prevention in Twin Gestation with a short cervix |
| Maternal Fetal Medicine |
Bergman, Anne |
Columbia University |
SLEEP CPAP (AAAR8244) |
A Randomized Trial of Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy (SLEEP) |
| Maternal Fetal Medicine |
Beche, Imene |
Columbia University |
The CPR Study |
Cholestasis of pregnancy and the PR interval: the CPR study |
| Maternal Fetal Medicine |
Otarola, Sol |
Columbia University |
TOPS (AAAR1388) |
A Randomized trial of pessary in singleton pregnancies with a short cervix |
| Maternal Fetal Medicine |
Perez, Clara |
Columbia University |
TXA (AAAR6736) |
Tranexamic Acid for the prevention of obstetrical hemorrhage after cesarean delivery: A Randomized Controlled Trial |
| Maternal Fetal Medicine |
Perez, Clara |
Columbia University |
PACT |
Prescription After Cesarean Trial (PACT) |
| Maternal Fetal Medicine |
Beche, Imene |
Illumina |
NIPT-C00-002 (Denali) |
Prospective Collection of Whole Blood Specimens From Pregnant Women at Any Risk of Fetal Chromosomal Anomaly for the Development of a Noninvasive Prenatal Test |
| Maternal Fetal Medicine |
Beche, Imene |
Illumina |
RGH-014 (AAAR0695) |
Prospective Collection of Blood Specimens in Pregnant Women Diagnosed with Preterm Preeclampsia and/or Fetal Growth Restriction in Support of Molecular Assay Development |
| Maternal Fetal Medicine |
Otarola, Sol |
Natera |
14-024-NPT (SMART) |
SNP-based Microdeletion and Aneuploidy RegisTry (SMART) (SMART) |
| Maternal Fetal Medicine |
Perez, Clara |
National Institute Of Health |
HCV study |
An Observational Study of Hepatitis C Virus in Pregancy |
| Maternal Fetal Medicine |
Sklios, Molly |
NICHD |
MFMU COVID-19 |
Maternal Morbidity and Mortality During during the COVID-19 Pandemic |
| Maternal Fetal Medicine |
Perez, Clara |
NICHD |
CMV Study |
A Randomized Trial to Prevent congenital cytomegalovirus infection CMV |
| Maternal Fetal Medicine |
Perez, Clara |
NICHD |
Pravastatin Preeclampsia |
A Randomized Controlled Trial of Pravastatin to Prevent Preeclampsia in High Risk Women |
| Maternal Fetal Medicine |
Otarola, Sol |
Pfizer |
C3671008 |
A Phase 3, Randomized, Double- Or Observer-Blinded, Placebo-Controlled Trial To Evaluate The Efficacy And Safety Of A Respiratory Syncytial Virus (Rsv) Prefusion F Subunit Vaccine In Infants Born To Women Vaccinated During Pregnancy |
| Maternal Fetal Medicine |
Perez, Clara |
Rutgers University |
PRN Collaboration (AAAR1870) |
Does the Cerebroplacental Ratio (CPR) Predict Adverse Outcomes in Low Risk Pregnancies? (CPR)RU010312017 |
| Maternal Fetal Medicine |
Beche, Imene |
Sequenom Inc |
SQNM-T21-107 |
Collection of Whole Blood Specimens from Pregnant Women at Increased Risk for Fetal Chromosomal Abnormality for use in Development of a Noninvasive Prenatal Test in the Detection of the Relative Quantity of Chromosomal Material in Circulating Cell-Free DNA Extracted from Maternal Plasma |
| Maternal Fetal Medicine |
Beche, Imene |
University of Alabama at Birmingham |
CHAP |
Chronic hypertension and Pregnancy Project (CHAP)1U01HL119242-01 |
| Maternal Fetal Medicine |
Otarola, Sol |
University of North Carolina |
MOMPOD |
Medical Optimization and Management of Pregnancies with Overt Type 2 Diabetes (MOMPOD) Study5R01HD086139-025109533 |
| OB/GYN |
Moser, Barbara |
SPUH |
Peri Cleansing Protocol |
Peri Cleansing Protocol for the Laboring Patient to Prevent Chorioamniotis: A Randomized Controlled Trial (PCP) |
| Pediatric Infectious Diseases |
Drost, Charlene |
University of Alabama at Birmingham |
DMID 19-0005 |
A Prospective Study Of Acute Flaccid Myelitis (Afm) To Define Natural History, Risk Factors, And Pathogenetic Mechanisms |
| Pediatric Infectious Diseases |
Drost, Charlene |
University of Alabama at Birmingham |
DMID 19-0026 |
Neonatal Enterovirus and Human Parechovirus Viral Sepsis: Natural History and Predictors of Morbidity and Mortality |
| Pediatric Neurology |
McMahan, Shona |
Aquestive (MonoSol) |
160325 |
A Multicenter, Open Label, Cross-Over Study to Assess the Pharmacokinetics and Safety of Diazepam Buccal Soluble Film (DBSF) in Pediatric Subjects with Epilepsy |
| Pediatric Neurology |
McMahan, Shona |
Aquestive (MonoSol) |
42-1703 |
An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Buccal Soluble Film (DBSF) in Pediatric, Adolescent and Adult Subjects With Epilepsy |
| Pediatric Neurology |
McMahan, Shona |
Eisai Inc. |
E2007-G000-238 |
An Open-Label Study With an Extension Phase to Evaluate the Pharmacokinetics of Perampanel (E2007) Oral Suspension When Given as an Adjunctive Therapy in Subjects From 1 Month to Less Than 4 Years of Age With Epilepsy |
| Pediatric Neurology |
McMahan, Shona |
Eisai Inc. |
E2007-G000-338 |
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Adjunctive Treatment in Subjects at Least 2 Years of Age With Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome |
| Pediatric Neurology |
McMahan, Shona |
Ovid Therapeutics |
TAK-935-18-001 (OV935) |
A Phase 2, Prospective, Interventional, Open-Label, Multi-Site, Extension Study To Assess The Long-Term Safety And Tolerability Of Tak-935 As Adjunctive Therapy In Patients With Rare Epilepsy |
| Pediatric Neurology |
McMahan, Shona |
Ovid Therapeutics |
TAK-935-2002 (ELEKTRA) |
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy, Safety, And Tolerability Of Tak-935 As An Adjunctive Therapy In Pediatric Patients With Developmental And/Or Epileptic Encephalopathies |
| Pediatric Neurology |
Vazquez-Telewoda, Kimberly |
Teva Pharmaceuticals |
TV50717-CNS-30080 |
A Randomized, Double-Blind, Placebo-Controlled Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents |
| Pediatric Neurology |
McMahan, Shona |
Teva Pharmaceuticals |
TV48125-CNS-30082 |
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age |
| Pediatric Neurology |
McMahan, Shona |
Teva Pharmaceuticals |
TV48125-CNS-30083 |
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age |
| Pediatric Neurology |
McMahan, Shona |
Teva Pharmaceuticals |
TV48125-CNS-30084 |
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age |
| Pediatric Neurology |
McMahan, Shona |
Teva Pharmaceuticals |
TV50717-CNS-30081 |
An Open Label, Long Term Safety, Tolerability and Efficacy Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents |
| Pediatric Neurology |
McMahan, Shona |
UCB Biosciences |
EP0065 |
A Multicenter, Open-Label Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Intravenous Brivaracetam In Subjects =1 Month To <16 Years Of Age With Epilepsy |
| Pediatric Neurology |
McMahan, Shona |
UCB Biosciences |
N01266 |
Open-Label, Single-Arm, Multicenter, Long-Term Follow-Up Study To Evaluate Safety And Efficacy Of Brivaracetam Used As Adjunctive Treatment In Pediatric Subjects With Epilepsy |
| Pediatric Neurology |
McMahan, Shona |
UCB Biosciences |
EP0093 |
An Open-Label, Multicenter, Extension Study To Evaluate The Safety And Efficacy Of Padsevonil As Adjunctive Treatment Of Focal-Onset Seizures In Adult Subjects With Drug-Resistant Epilepsy |
| Pediatric Oncology |
Zaidi, Naureen |
Childrens Oncology Group (COG) |
AALL1631 |
International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones |
| Pediatric Oncology |
Zaidi, Naureen |
Childrens Oncology Group (COG) |
AALL1731 |
A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy) |
| Pediatric Oncology |
Zaidi, Naureen |
Childrens Oncology Group (COG) |
AALL1732 |
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy |
| Pediatric Oncology |
Zaidi, Naureen |
Childrens Oncology Group (COG) |
ACNS1422 |
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma |
| Pediatric Oncology |
Zaidi, Naureen |
Childrens Oncology Group (COG) |
ACNS1721 |
A Phase 2 Study of Veliparib (ABT-888, IND# 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations |
| Pediatric Oncology |
Zaidi, Naureen |
Childrens Oncology Group (COG) |
AGCT1532 (ANZUP 1302) |
A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours |
| Pediatric Oncology |
Zaidi, Naureen |
Childrens Oncology Group (COG) |
ALTE03N1 |
Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors |
| Pediatric Oncology |
Zaidi, Naureen |
Childrens Oncology Group (COG) |
ALTE05N1 |
Umbrella Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies |
| Pediatric Oncology |
Zaidi, Naureen |
Childrens Oncology Group (COG) |
ANBL00B1 |
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma |
| Pediatric Oncology |
Zaidi, Naureen |
Childrens Oncology Group (COG) |
ANBL1232 |
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma |
| Pediatric Oncology |
Zaidi, Naureen |
Childrens Oncology Group (COG) |
APEC14B1 |
EveryChild A Registry, Eligibility Screening, Biology and Outcome Study |
| Pediatric Oncology |
Zaidi, Naureen |
Childrens Oncology Group (COG) |
APEC1621A |
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) |
| Pediatric Oncology |
Zaidi, Naureen |
Childrens Oncology Group (COG) |
APEC1621B |
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) |
| Pediatric Oncology |
Zaidi, Naureen |
Childrens Oncology Group (COG) |
APEC1621D |
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) |
| Pediatric Oncology |
Zaidi, Naureen |
Childrens Oncology Group (COG) |
APEC1621F |
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) |
| Pediatric Oncology |
Zaidi, Naureen |
Childrens Oncology Group (COG) |
APEC1621G |
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) |
| Pediatric Oncology |
Zaidi, Naureen |
Childrens Oncology Group (COG) |
APEC1621H |
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) |
| Pediatric Oncology |
Zaidi, Naureen |
Childrens Oncology Group (COG) |
APEC1621SC (MATCH) |
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) |
| Pediatric Oncology |
Zaidi, Naureen |
Childrens Oncology Group (COG) |
AREN03B2 |
Renal Tumors Classification, Biology, and Banking Study |
| Pediatric Oncology |
Zaidi, Naureen |
Childrens Oncology Group (COG) |
ARST1431 |
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS) |
| Pediatric Oncology |
Zaidi, Naureen |
Childrens Oncology Group (COG) |
AALL15P1 |
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement |
| Pediatric Oncology |
Zaidi, Naureen |
Childrens Oncology Group (COG) |
AALL1621 |
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND# 133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL) |
| Pediatric Oncology |
Zaidi, Naureen |
Childrens Oncology Group (COG) |
AEWS1221 |
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma |
| Pediatric Oncology |
Zaidi, Naureen |
Childrens Oncology Group (COG) |
AHOD1331 |
A Randomized Phase III Study of Brentuximab Vedotin Newly Diagnosed High-Risk Classical Hodgkin Lymphoma in Children and Adolescents |
| Pediatric Oncology |
Zaidi, Naureen |
Childrens Oncology Group (COG) |
APEC1621C |
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) |
| Pediatric Oncology |
Zaidi, Naureen |
Childrens Oncology Group (COG) |
APEC11621E |
Selumetinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) |
| Pediatrics |
|
SPUH |
Biomarker Memory in ASD |
Biomarkers of Innate Immune Memory in Autism Spectrum DisordersNJ Gov Council Grant |
| Radiation Oncology |
Vazquez-Telewoda, Kimberly |
Alliance |
A011502 |
A Randomized Phase Iii Double Blinded Placebo Controlled Trial Of Aspirin As Adjuvant Therapy For Her2 Negative Breast Cancer: The Abc Trial |
| Radiation Oncology |
Vazquez-Telewoda, Kimberly |
Alliance |
DCP-001 |
Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP) |
| Radiation Oncology |
Vazquez-Telewoda, Kimberly |
CCTG |
MA.39 (Tailor RT) |
Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer(CCTGMA.39) |
| Radiation Oncology |
Vazquez-Telewoda, Kimberly |
Crozer-Keystone Health Systems |
CK-DESPOT |
CyberKnife Dose Escalation Prostate Cancer Trial (CK-DESPOT) |
| Radiation Oncology |
Vazquez-Telewoda, Kimberly |
Radiosurgery Society |
RSSearch Patient Registry |
RSSearch Patient Registry for Patients who may be Treated with Radiosurgery at Saint Peter's University Hospital |
| Radiation Oncology |
Vazquez-Telewoda, Kimberly |
SPUH |
Breast Cyberknife |
A Pilot Study of Partial Breast CyberKnife® for Postmenopausal Women 50 Years of Age or Older with DCIS or Stage I Breast Cancer |
| Radiation Oncology |
Vazquez-Telewoda, Kimberly |
SPUH |
Lung Cancer Registry |
Lung cancer registry study - Cyberknife® Radiosurgery VS external beam radiation therapy |
